Not available
Quote | Lantheus Holdings Inc. (NASDAQ:LNTH)
Last: | $81.83 |
---|---|
Change Percent: | -0.37% |
Open: | $80.82 |
Close: | $81.83 |
High: | $82.083 |
Low: | $80.69 |
Volume: | 824,277 |
Last Trade Date Time: | 05/31/2024 03:00:00 am |
News | Lantheus Holdings Inc. (NASDAQ:LNTH)
2024-06-01 09:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
BEDFORD, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced Paul Blanchfie...
Message Board Posts | Lantheus Holdings Inc. (NASDAQ:LNTH)
Subject | By | Source | When |
---|---|---|---|
Interesting 8K announcing Paul Blanchfield's move to COO. | Chuckles759 | investorshub | 06/16/2022 5:14:18 AM |
I'm thinking that nothing of significance was announced/presented | Chuckles759 | investorshub | 06/10/2022 6:38:43 PM |
Any thoughts if something newsworthy will be announced | Chuckles759 | investorshub | 06/06/2022 11:59:50 AM |
$lnth covered in fake bots on this site. | make it happen | investorshub | 05/27/2022 1:52:43 PM |
Can't fault Gerald Ber for cashing in a | Chuckles759 | investorshub | 05/13/2022 5:53:13 PM |
News, Short Squeeze, Breakout and More Instantly...
Lantheus Holdings Inc. Company Name:
LNTH Stock Symbol:
NASDAQ Market:
2024-06-01 09:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
BEDFORD, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced Paul Blanchfie...
Jeffrey S. Humphrey, MD appointed Chief Medical Officer;Jean-Claude Provost, MD named Chief Science Officer BEDFORD, Mass., May 15, 2024 (GLOBE ...